Article citationsMore>>

Clere, N., Corre, I., Faure, S., Guihot, A.L., Vessières, E., Chalopin, M., Morel, A., Coqueret, O., Hein, L., Delneste, Y., Paris, F. and Henrion, D. (2010) Deficiency or Blockade of Angiotensin II Type 2 Receptor Delays Tumorigenesis by Inhibiting Malignant Cell Proliferation and Angiogenesis. International Journal of Cancer, 127, 2279-2291.
http://dx.doi.org/10.1002/ijc.25234

has been cited by the following article:

• TITLE: Renin Angiotensin System Components and Cancer: Reports of Association

  AUTHORS: Maria Del Carmen Garcia Molina Wolgien, Silvana Aparecida Alves Correa, Pedro Alexandre Federico Breuel, Afonso Celso Pinto Nazário, Gil Facina

  KEYWORDS: Renin-Angiotensin System, Angiotensin Converting Enzyme, Angiotensin Type 1 Receptor, Angiotensin Type 2 Receptor, Breast Cancer, Cancer

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.4 No.5, May 19, 2016

  ABSTRACT: Renin-Angiotensin System (RAS) is involved with hypertension and other cardiovascular diseases. However, the association of RAS components to cancer still causes suspicion. To try to clarify this, here we aimed to show this association for three important components: Angiotensin Converting Enzyme 1 (ACE1), Angiotensin Type 1 Receptor (AGTR1) and Angiotensin Type 2 Receptor (AGTR2). The first articles show that association of RAS components with cancer dates back to the 70’s. ECA1 and AGTR1 have close association with cancer and ACE1 inhibitors or AGTR1 blockers are candidates to treatment of some tumors. Moreover, the action of AGTR2 is still controversial, but most studies show that the increased expression of AGTR2 can attack the cancer cells. In breast cancer, these components have also been widely studied and many works have shown that the correlation exists. Therefore specific target using these RAS components could be a beneficial, novel therapy to various tumors.